Many studies have shown that targeting Smad3 can improve the development and progression of tissue fibrosis in vivo, including experimental models of renal fibrosis, pulmonary fibrosis, and liver fibrosis [43,44,45,46]. Here, SMAD3 is linked to pulmonary fibrosis.